<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066507</url>
  </required_header>
  <id_info>
    <org_study_id>ASI-Her2F</org_study_id>
    <nct_id>NCT01066507</nct_id>
  </id_info>
  <brief_title>Detection of Amplification of Her2 Fluorescent in Situ Hybridization (FISH) in Breast Tissue Sections</brief_title>
  <acronym>Her2F test</acronym>
  <official_title>Concordance Study for Amplification Detection of Her2 FISH in Breast Tissue Sections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Spectral Imaging Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Applied Spectral Imaging Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is the identification of amplification level in human breast tissue.
      The imaging system is intended for diagnostic use as an aid to the pathologist in the
      detection, counting and classification of Her2 FISH stained tissue samples.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">126</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast cancer</arm_group_label>
    <description>Slides containing breast cancer paraffin embedded tissue sections.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Paraffin embedded tissue sections
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The breast samples were taken from female patients after cut biopsies. Paraffin embedded
        blocks were prepared and the secssion slides were stained with the PathVysion prove for
        Her2 FISH applification detection
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Well stained breast tissue slides with bright Her2 signals

        Exclusion Criteria:

          -  Very old slides that were already bleached
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheila Dobin, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Section Chief, Cytogenetics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PLUS Diagnostics</name>
      <address>
        <city>Lakewood</city>
        <state>New Jersey</state>
        <zip>08701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Hospital, Texas</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center, Pathology Dep.</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <last_update_submitted>February 9, 2010</last_update_submitted>
  <last_update_submitted_qc>February 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Tsafrir Kolatt</name_title>
    <organization>Applied Spectral Imaging Ltd.</organization>
  </responsible_party>
  <keyword>Her2</keyword>
  <keyword>FISH</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Amplification</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

